ReviewBMC anesthesiology2026
Local anesthetic systemic toxicity with liposomal bupivacaine: a case series and literature review.
Review in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLocal Anesthetic Systemic Toxicity (LAST) is an uncommon complication, with manifestations ranging from mild, non-specific neurological symptoms to severe cardiac arrest. Toxicity specifically associated with liposomal bupivacaine is even more rarely documented in the literature. We report two cases of LAST following the administration of liposomal bupivacaine and provide a review of previously reported cases. CASE PRESENTATION: Case 1: A 55-year-old male received 266 mg of liposomal bupivacaine via intercostal nerve block during thoracoscopic lobectomy. During skin closure, he developed cardiac arrest and recurrent ventricular fibrillation. He was successfully extubated and weaned off all vasopressors two hours after lipid emulsion administration and subsequently recovered. Case 2: A 67-year-old male received 266 mg of liposomal bupivacaine via incision infiltration after lobectomy. Shortly after PACU arrival, he developed agitation, fixed gaze, and increased muscle tone. Lipid emulsion infusion led to neurological improvement within five minutes, and he was subsequently discharged successfully.
conclusionsThese two cases highlight the potential for catastrophic LAST associated with liposomal bupivacaine. To mitigate this risk, we recommend reducing the dose of local anesthetics when injecting into highly vascular areas and performing careful aspiration during injection to prevent intravascular injection. Furthermore, the early administration of intravenous lipid emulsion should be strongly considered upon any suspicion of LAST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.